Abstract: The invention relates to anhydrides, solvates and ethanol hetero-solvates and hydrates of dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?, 10?-dimethoxy-9-oxo-tax-11-ene-13?-yle, and to the preparation thereof.
Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Type:
Grant
Filed:
August 7, 2014
Date of Patent:
January 10, 2017
Assignees:
Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
Abstract: The present invention relates to a novel crystalline ethyl acetate solvate form of cabazitaxel or 4?-acetoxy-2?-benzoyloxy-5?,20-epoxy-1?-hydroxy-7?,10?-dimethoxy-9-oxo-11-taxen-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and process for preparing the same.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
April 12, 2016
Assignee:
AVENTIS PHARMA S.A.
Inventors:
Eric Didier, Nicolas Tremaudeux, Lionel Zaske
Abstract: The disclosure relates to compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as defined in the disclosure, to the compositions containing them and to the use thereof as medicaments, in particular as anticancer agents. The disclosure also relates to the process for preparing the compounds of formula (I) and to reaction intermediates.
Type:
Grant
Filed:
December 18, 2008
Date of Patent:
September 8, 2015
Assignee:
AVENTIS PHARMA S.A.
Inventors:
Marie-Pierre Cherrier, Eric Parmantier, Hervé Minoux, François Clerc, Odile Angouillant-Boniface, Maurice Brollo, Laurent Schio
Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Type:
Application
Filed:
August 7, 2014
Publication date:
March 12, 2015
Applicants:
Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
Abstract: The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease.
Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Type:
Grant
Filed:
August 15, 2011
Date of Patent:
September 16, 2014
Assignees:
Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
Abstract: The present invention relates to new nucleotide sequences coding for variable regions of ? chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.
Abstract: The invention concerns the production of cholesterol of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
April 1, 2014
Assignee:
Aventis Pharma S.A.
Inventors:
Denis Pompon, Bruno Dumas, Roberto Spagnoli
Abstract: The present invention relates to a pharmaceutical formulation of ketoprofen sodium salts in a hydrophilic solvent system suitable as a liquid fill composition. In another aspect, the invention also relates to a process for the preparation of a pharmaceutical formulation and the use of the formulation for treating inflammatory pains.
Abstract: The present invention relates to a combination comprising cabazitaxel and cisplatin. The present invention relates also to a pharmaceutical composition containing such a combination and to a pharmaceutical kit comprising: (i) a first galenic formulation comprising cabazitaxel; and (ii) a second galenic formulation comprising cisplatin. The invention relates also to the use of this combination and/or pharmaceutical composition and/or pharmaceutical kit in the treatment of neoplastic diseases, more particularly in the treatment of cancer.
Type:
Application
Filed:
August 22, 2013
Publication date:
February 27, 2014
Applicant:
Aventis Pharma S.A.
Inventors:
Marie-Christine BISSERY, Jean-Francois DEDIEU, Akbar KHAN, Patricia VRIGNAUD
Abstract: The present invention is directed to an affinity chromatography column comprising the antithrombin III (ATIII) protein bound to a solid support, characterized in that: a. the ATIII protein is the wild-type protein or a variant thereof, b. the ATIII protein has been first activated by incubation with an unmodified low-molecular-weight heparin (LMWH) rich in active species, and c. the ATIII protein is covalently bound to a resin in a ratio of less than approximately 2 mg of protein per ml of hydrated resin. The invention is also directed to the use of the aforesaid column for purifying species having an affinity for ATIII in a sample comprising species having affinity and not having affinity for ATIII.
Abstract: Recombinant viruses comprising a heterologous. DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.
Abstract: The present invention relates to the field of transgenic animal models and more particularly the animal models of Alzheimer's disease. The invention relates to a transgenic animal expressing a multimutated form of presenilin 1 and allowing an apoptotic phenomenon to be detected in a renewable peripheral tissue.
Type:
Grant
Filed:
September 22, 2000
Date of Patent:
July 23, 2013
Assignee:
Aventis Pharma S.A.
Inventors:
Anne Eckert, Walter Muller, Christian Czech, Laurent Pradier, Gunter Tremp
Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
Type:
Application
Filed:
March 4, 2013
Publication date:
July 18, 2013
Applicants:
Aventis Pharma S.A., Regeneron Pharmaceuticals, Inc.
Abstract: The invention relates to anhydrides, solvates and ethanol hetero-solvates and hydrates of dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?, 10?-dimethoxy-9-oxo-tax-11-ene-13?-yle, and to the preparation thereof.
Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
Type:
Grant
Filed:
January 11, 2012
Date of Patent:
July 9, 2013
Assignee:
Aventis Pharma S.A.
Inventors:
Francis Blanche, Béatrice Cameron, Sylvie Sordello, Céline Nicolazzi, Marc Trombe, Mark Nesbit